Resveratrol ameliorates the anxiety- and depression-like behavior of subclinical hypothyroidism rat: Possible involvement of the HPT axis, HPA axis, and Wnt/β-catenin pathway

Frontiers in Endocrinology

Volumn 7, Issue MAY, 2016, Pages

  Ge, Jin Fang ^a   Xu, Ya Yun ^a   Qin, Gan ^a   Cheng, Jiang Qun ^a   Chen, Fei Hu ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Depression; Hypothalamic pituitary thyroid axis; Hypothalamus pituitary adrenal axis; Resveratrol; Subclinical hypothyroidism; Wnt catenin pathwa

Indexed keywords

BETA CATENIN; CORTICOSTERONE; GLYCOGEN SYNTHASE KINASE 3BETA; PROTIRELIN; RESVERATROL; THYROTROPIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CAUTERIZATION; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; EXPERIMENTAL BEHAVIORAL TEST; FORCED SWIM TEST; HIPPOCAMPUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; OPEN FIELD TEST; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBCLINICAL HYPOTHYROIDISM; SUCROSE PREFERENCE TEST; UPREGULATION; WESTERN BLOTTING;

EID: 84975256620     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2016.00044     Document Type: Article

References (55)

1. He XS, Ma N, Pan ZL, Wang ZX, Li N, Zhang XC, et al. Functional magnetic resource imaging assessment of altered brain function in hypothyroidism during working memory processing. Eur J Endocrinol (2011) 164:951-9. doi: 10.1530/EJE-11-0046
2. Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, Hu XP, et al. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain (2006) 129:2923-30. doi:10.1093/brain/awl215
3. Chueire VB, Romaldini JH, Ward LS. Subclinical hypothyroidism increases the risk for depression in the elderly. Arch Gerontol Geriatr (2007) 44:21-8. doi:10.1016/j.archger.2006.02.001
4. Davis JD, Stern RA, Flashman LA. Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: significance in the elderly. Curr Psychiatry Rep (2003) 5:384-90. doi:10.1007/s11920-003-0073-6
5. Almeida C, Brasil MA, Costa AJ, Reis FA, Reuters V, Teixeira P, et al. Subclinical hypothyroidism: psychiatric disorders and symptoms. Rev Bras Psiquiatr (2007) 29:157-9. doi:10.1590/S1516-44462007000200013
6. Ge JF, Peng YY, Qi CC, Chen FH, Zhou JN. Depression-like behavior in subclinical hypothyroidism rat induced by hemi-thyroid electrocauterization. Endocrine (2014) 45:430-8. doi:10.1007/s12020-013-0001-4
7. Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler LL, et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry (2005) 10:456-69. doi:10.1038/sj.mp.4001647
8. Uhl I, Bez JA, Stamm T, Pilhatsch M, Assion HJ, Norra C, et al. Influence of levothyroxine in augmentation therapy for bipolar depression on central serotonergic function. Pharmacopsychiatry (2014) 47:180-3. doi:10.1055/s-0034-1383654
9. Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res (2014) 58:7-21. doi:10.1002/mnfr.201200589
10. Shin SM, Cho IJ, Kim SG. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol (2009) 76:884-95. doi:10.1124/mol.109.058479
11. Ge JF, Peng L, Cheng JQ, Pan CX, Tang J, Chen FH, et al. Antidepressant-like effect of resveratrol: involvement of antioxidant effect and peripheral regulation on HPA axis. Pharmacol Biochem Behav (2013) 11(4-115):64-9. doi:10.1016/j.pbb.2013.10.028
12. Hurley LL, Akinfiresoye L, Kalejaiye O, Tizabi Y. Antidepressant effects of resveratrol in an animal model of depression. Behav Brain Res (2014) 268:1-7. doi:10.1016/j.bbr.2014.03.052
13. Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Curr Top Behav Neurosci (2011) 7:121-47. doi:10.1007/7854_2010_108
14. Liu D, Zhang Q, Gu J, Wang X, Xie K, Xian X, et al. Resveratrol prevents impaired cognition induced by chronic unpredictable mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry (2014) 49:21-9. doi:10.1016/j.pnpbp.2013.10.017
15. Poirier GL, Imamura N, Zanoletti O, Sandi C. Social deficits induced by peripubertal stress in rats are reversed by resveratrol. J Psychiatr Res (2014) 57:157-64. doi:10.1016/j.jpsychires.2014.05.017
16. Yu Y, Wang R, Chen C, Du X, Ruan L, Sun J, et al. Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res (2013) 47:315-22. doi:10.1016/j.jpsychires.2012.10.018
17. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci (2014) 34:7862-70. doi:10.1523/JNEUROSCI.0385-14.2014
18. Chow HH, Garland LL, Heckman-Stoddard BM, Hsu CH, Butler VD, Cordova CA, et al. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J Transl Med (2014) 12:223. doi:10.1186/s12967-014-0223-0
19. Xu Y, Wang Z, You W, Zhang X, Li S, Barish PA, et al. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol (2010) 20:405-13. doi:10.1016/j.euroneuro.2010.02.013
20. Brenes Saenz JC, Villagra OR, Fornaguera Trias J. Factor analysis of forced swimming test, sucrose preference test and open field test on enriched, social and isolated reared rats. Behav Brain Res (2006) 169:57-65. doi:10.1016/j.bbr.2005.12.001
21. de Sousa RT, Zanetti MV, Talib LL, Serpa MH, Chaim TM, Carvalho AF, et al. Lithium increases platelet serine-9 phosphorylated GSK-3beta levels in drug-free bipolar disorder during depressive episodes. J Psychiatr Res (2015) 62:78-83. doi:10.1016/j.jpsychires.2015.01.016
22. Karege F, Perroud N, Burkhardt S, Fernandez R, Ballmann E, La Harpe R, et al. Protein levels of beta-catenin and activation state of glycogen synthase kinase-3beta in major depression. A study with postmortem prefrontal cortex. J Affect Disord (2012) 136:185-8. doi:10.1016/j.jad.2011.09.024
23. Voleti B, Duman RS. The roles of neurotrophic factor and Wnt signaling in depression. Clin Pharmacol Ther (2012) 91:333-8. doi:10.1038/clpt.2011.296
24. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry (2004) 55:781-4. doi:10.1016/j.biopsych.2004.01.008
25. Wang L, Shao YY, Ballock RT. Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J Bone Miner Res (2007) 22:1988-95. doi:10.1359/jbmr.070806
26. Walsh RN, Cummins RA. The open-field test: a critical review. Psychol Bull (1976) 83:482-504. doi:10.1037/0033-2909.83.3.482
27. Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med (2001) 345:260-5. doi:10.1056/NEJM200107263450406
28. Farmer A, Korszun A, Owen MJ, Craddock N, Jones L, Jones I, et al. Medical disorders in people with recurrent depression. Br J Psychiatry (2008) 192:351-5. doi:10.1192/bjp.bp.107.038380
29. Najafi L, Malek M, Hadian A, Ebrahim Valojerdi A, Khamseh ME, Aghili R. Depressive symptoms in patients with subclinical hypothyroidism-the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocr Res (2015) 40(3):121-6. doi:10.3109/07435800.2014.896924
30. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med (2000) 160:526-34. doi:10.1001/archinte.160.4.526
31. Behr GA, Moreira JC, Frey BN. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev (2012) 2012:609421. doi:10.1155/2012/609421
32. Reus GZ, Dos Santos MA, Abelaira HM, Titus SE, Carlessi AS, Matias BI, et al. Antioxidant treatment ameliorates experimental diabetes-induced depressive-like behavior and reduces oxidative stress in brain and pancreas. Diabetes Metab Res Rev (2016) 32:278-88. doi:10.1002/dmrr.2732
33. Li H, Yan Z, Zhu J, Yang J, He J. Neuroprotective effects of resveratrol on ischemic injury mediated by improving brain energy metabolism and alleviating oxidative stress in rats. Neuropharmacology (2011) 60:252-8. doi:10.1016/j.neuropharm.2010.09.005
34. Akieda-Asai S, Zaima N, Ikegami K, Kahyo T, Yao I, Hatanaka T, et al. SIRT1 regulates thyroid-stimulating hormone release by enhancing PIP5Kgamma activity through deacetylation of specific lysine residues in mammals. PLoS One (2010) 5:e11755. doi:10.1371/journal.pone.0011755
35. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (1995) 121:66-72. doi:10.1007/BF02245592
36. Geffken GR, Ward HE, Staab JP, Carmichael SL, Evans DL. Psychiatric morbidity in endocrine disorders. Psychiatr Clin North Am (1998) 21:473-89. doi:10.1016/S0193-953X(05)70017-4
37. Miller KJ, Parsons TD, Whybrow PC, van Herle K, Rasgon N, van Herle A, et al. Memory improvement with treatment of hypothyroidism. Int J Neurosci (2006) 116:895-906. doi:10.1080/00207450600550154
38. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in l-thyroxine-treated hypothyroid subjects. Thyroid (2007) 17:249-58. doi:10.1089/thy.2006.0252
39. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev (2005) 4:141-94. doi:10.1016/j.arr.2005.03.003
40. Li D, Dammer EB, Sewer MB. Resveratrol stimulates cortisol biosynthesis by activating SIRT-dependent deacetylation of P450scc. Endocrinology (2012) 153:3258-68. doi:10.1210/en.2011-2088
41. Wang Z, Gu J, Wang X, Xie K, Luan Q, Wan N, et al. Antidepressant-like activity of resveratrol treatment in the forced swim test and tail suspension test in mice: the HPA axis, BDNF expression and phosphorylation of ERK. Pharmacol Biochem Behav (2013) 112:104-10. doi:10.1016/j.pbb.2013.10.007
42. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry (2007) 61:240-5. doi:10.1016/j.biopsych.2006.04.036
43. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets (2006) 7:1421-34. doi:10.2174/1389450110607011421
44. O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci (2004) 24:6791-8. doi:10.1523/JNEUROSCI.4753-03.2004
45. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science (2000) 287:1606-9. doi:10.1126/science.287.5458.1606
46. Yu X, Malenka RC. Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci (2003) 6:1169-77. doi:10.1038/nn1132
47. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J (1998) 329(Pt 2):209-23. doi:10.1042/bj3290209
48. Pilar-Cuellar F, Vidal R, Pazos A. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects. Br J Pharmacol (2012) 165:1046-57. doi:10.1111/j.1476-5381.2011.01516.x
49. Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol (2005) 11:2117-23. doi:10.3748/wjg.v11.i14.2117
50. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, et al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics (2013) 8:1373-83. doi:10.4161/epi.26781
51. Brabletz T, Jung A, Dag S, Reu S, Kirchner T. [beta-Catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma]. Verh Dtsch Ges Pathol (2000) 84:175-81.
52. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev (2007) 16:1246-52. doi:10.1158/1055-9965.EPI-07-0022
53. Helfand MU.S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2004) 140:128-41. doi:10.7326/0003-4819-140-2-200401200-00015
54. Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms. Curr Med Chem (2013) 20:4640-5. doi:10.2174/09298673113209990151
55. Timmers S, Hesselink MK, Schrauwen P. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci (2013) 1290:83-9. doi:10.1111/nyas.12185